Screener
Polaryx Therapeutics, Inc. PLYX Accrued Research And Development Expenses
Accrued Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept plyx:AccruedResearchAndDevelopmentExpenses.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
FAQ
- What is Polaryx Therapeutics, Inc.'s accrued research and development expenses?
- Polaryx Therapeutics, Inc. (PLYX) reported accrued research and development expenses of $86K in Q4 2024.
- What does accrued research and development expenses mean?
- Liabilities recognized for research and development services that have been performed but not yet invoiced or paid. This reflects the company's commitment to ongoing clinical trials and scientific development.
Ask your AI about Polaryx Therapeutics, Inc.'s accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude